While novel FLT3 inhibitors have been, or will be, approved for use as single agents in the treatment of acute myeloid leukemia (AML). Here, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the increased efficacy of these drugs when combined with chemotherapy. Dr Perl states how newer generation FLT3 inhibitors in combination with chemotherapy may improve response rates and survival benefits in the frontline setting. He mentions that the future of FLT3 inhibitors as a combination therapy is continuously improving, which is exciting to witness. This interview was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX.